News | October 25, 2021
Biocon reports a consolidated net profit of Rs. 138.3 crore in Q2FY22
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
Second interchangeable biosimilar product approved by agency
U.S. FDA to decide whether to authorize a booster dose in the coming days
The company plans to submit the IND application by the end of 2021
The company does not expect the outcome of this inspection to impact its plans
Subscribe To Our Newsletter & Stay Updated
